The corporate has constructed an end-to-end AI-based platform that comprehensively maps the course of a illness on the protein degree.
Israeli AI-powered drug discovery firm Protai immediately introduced the completion of an $8 million seed financing spherical co-led by Grove Ventures and Pitango HealthTech. The corporate mentioned that the brand new funding will likely be used to develop its platform, speed up its discovery applications and improve partnerships with pharmaceutical corporations.
Protai, which was solely based final yr, has constructed an end-to-end AI-based platform that comprehensively maps the course of a illness on the protein degree, enhancing the flexibility to watch mobile perform and thereby enhancing the best way new medicine are found. This method permits Protai to extend accuracy in drug discovery and enhance the event course of, considerably saving time and decreasing the prices of R&D.
Protai cofounder and CEO Eran Seger mentioned, “Protai’s platform is sort of a distinctive compass for guiding drug discovery. We’re systematically mapping ailments on the protein degree to create a wholly new layer of purposeful data which allows us to establish therapeutic and diagnostic targets to higher fight a variety of advanced ailments.”
Protai claims to have created the world’s largest and most various proteomic database with over 50,000 medical samples by harmonizing giant medical datasets, in addition to wholesome samples from numerous organs and indications. This allows Protai to determine a baseline to then precisely simulate organic purposeful processes for a wide range of ailments and speed up drug R&D by way of medical and preclinical levels.
Printed by Globes, Israel enterprise information – en.globes.co.il – on January 5, 2022.
© Copyright of Globes Writer Itonut (1983) Ltd., 2022.
Portai staff Picture: David Karp